BioToxTech Co

BioToxTech Co Short-term Debt

The Short-Term Debt of BioToxTech Co (086040.KQ) as of Nov 12, 2026 is 22.19 B KRW. In the previous year, Short-Term Debt was 23.83 B KRW — a change of -6.88% (lower).

Short-term Debt

22.19 BKRW

YoY

-6.88%

Last updated:

Short-Term Debt of BioToxTech Co is 2024 22.19 B KRW. Short-Term Debt of BioToxTech Co was 2023 23.83 B KRW. It decreases by -6.88% lower compared to the previous year.

The BioToxTech Co Short-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Short-term Debt
Date
Short-term Debt
Jan 1, 2017
14.70 B KRW
Jan 1, 2018
15.26 B KRW
Jan 1, 2019
10.68 B KRW
Jan 1, 2020
9.41 B KRW
Jan 1, 2021
13.34 B KRW
Jan 1, 2022
14.35 B KRW
Jan 1, 2023
23.83 B KRW
Jan 1, 2024
22.19 B KRW
The BioToxTech Co Short-term Debt history
YEARShort-term DebtYoY
22.19 BKRW-6.88%
23.83 BKRW+66.08%
14.35 BKRW+7.55%
13.34 BKRW+41.86%
9.41 BKRW-11.90%
10.68 BKRW-30.05%
15.26 BKRW+3.86%
14.70 BKRW+8.96%
13.49 BKRW-4.39%
14.11 BKRW+464.32%
2.50 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioToxTech Co Stock analysis

What does BioToxTech Co do? Biotoxtech Co., Ltd. generates revenue through non-clinical drug trials, offering safety evaluation research, efficacy evaluation research, and analysis research services. Safety evaluation includes general toxicity, local toxicity, reproductive and development, genotoxicity, immunotoxicity, carcinogenicity, safety pharmacology, ecotoxicology, histopathology, and hematology tests. Efficacy evaluation covers medical supplies, health supplements, and cosmetics. Analysis research provides pharmacokinetics (PK) and toxicokinetics (TK) tests, validation, and bio analysis services. The company serves clients requiring preclinical testing for pharmaceuticals, health products, and cosmetics. The firm expanded its operations by acquiring a 60% stake in a newly established subsidiary on March 13, 2013. This strategic move enhances its capacity to deliver comprehensive research services. Clients include pharmaceutical companies, health supplement manufacturers, and cosmetic brands seeking regulatory compliance and product safety validation before market entry. Biotoxtech's service portfolio targets the pharmaceutical, health supplement, and cosmetic industries. Its safety and efficacy testing ensures products meet regulatory standards, supporting clients in developing safe and effective formulations. The company's analysis research further aids in optimizing drug delivery and performance through PK and TK assessments. BioToxTech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioToxTech Co stock

Short-Term Debt of BioToxTech Co is 22.19 B KRW in 2024.

Short-Term Debt of BioToxTech Co changed from 23.83 B KRW to 22.19 B KRW, representing a -6.88% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Short-Term Debt BioToxTech Co since 2006 – with annual values, charts, and detailed analysis.

Short-term debt represents borrowings due within one year. High short-term debt relative to cash can signal liquidity risk.

Short-Term Debt's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Short-Term Debt's BioToxTech Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — BioToxTech Co

All Key Metrics — BioToxTech Co